SpringWorks Deferred Long Term Liab vs Current Deferred Revenue Analysis

SWTX Stock

USD 45.11 1.76 4.06%

SpringWorks Therapeutics financial indicator trend analysis is much more than just breaking down SpringWorks Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether SpringWorks Therapeutics is a good investment. Please check the relationship between SpringWorks Therapeutics Deferred Long Term Liab and its Current Deferred Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SpringWorks Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy SpringWorks Stock please use our How to Invest in SpringWorks Therapeutics guide.

Deferred Long Term Liab vs Current Deferred Revenue

Deferred Long Term Liab vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of SpringWorks Therapeutics Deferred Long Term Liab account and Current Deferred Revenue. At this time, the significance of the direction appears to have very strong relationship.

The correlation between SpringWorks Therapeutics' Deferred Long Term Liab and Current Deferred Revenue is 0.88. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of SpringWorks Therapeutics, assuming nothing else is changed. The correlation between historical values of SpringWorks Therapeutics' Deferred Long Term Liab and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of SpringWorks Therapeutics are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Deferred Long Term Liab i.e., SpringWorks Therapeutics' Deferred Long Term Liab and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.88

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from SpringWorks Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into SpringWorks Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SpringWorks Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy SpringWorks Stock please use our How to Invest in SpringWorks Therapeutics guide.At this time, SpringWorks Therapeutics' Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 38.08 in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 237.1 M in 2024.

	2021	2022	2023	2024 (projected)
Cost Of Revenue	490K	1.9M	422K	400.9K
Research Development	101.7M	146.1M	150.5M	158.0M

Cost Of Revenue Research Development

SpringWorks Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Short Term Investments	Inventory	Other Current Assets	Total Liab	Treasury Stock	Intangible Assets	Common Stock	Property Plant Equipment	Long Term Debt	Preferred Stock Total Equity	Good Will	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments
Total Assets		0.91	0.8	0.53	0.82	0.43	0.7	0.84	0.12	0.19	0.94	0.69	0.64	0.31	0.65	0.28	-0.19	-0.64	-0.64	0.94	0.86	-0.68	-0.89	0.82	0.94	0.95
Other Current Liab	0.91		0.9	0.51	0.92	0.51	0.54	0.75	0.02	0.34	0.97	0.85	0.83	0.31	0.79	0.37	-0.14	-0.84	-0.84	0.77	0.98	-0.52	-0.99	0.94	0.84	0.76
Total Current Liabilities	0.8	0.9		0.41	0.8	0.83	0.42	0.81	-0.34	0.69	0.86	0.89	0.73	-0.13	0.87	0.73	0.3	-0.74	-0.74	0.64	0.86	-0.41	-0.87	0.82	0.7	0.63
Total Stockholder Equity	0.53	0.51	0.41		0.33	0.09	0.63	0.36	-0.31	0.22	0.59	0.28	0.6	0.25	0.45	0.0	-0.13	-0.6	-0.6	0.45	0.35	-0.63	-0.43	0.72	0.48	0.37
Other Liab	0.82	0.92	0.8	0.33		0.43	0.39	0.76	0.09	0.2	0.93	0.76	0.68	0.34	0.66	0.28	-0.21	-0.69	-0.69	0.71	0.9	-0.37	-0.94	0.82	0.82	0.71
Accounts Payable	0.43	0.51	0.83	0.09	0.43		0.16	0.66	-0.64	0.9	0.48	0.67	0.34	-0.65	0.68	0.98	0.76	-0.34	-0.34	0.32	0.47	-0.17	-0.46	0.37	0.34	0.33
Cash	0.7	0.54	0.42	0.63	0.39	0.16		0.46	0.09	0.02	0.62	0.31	0.42	0.31	0.33	0.0	-0.24	-0.43	-0.43	0.69	0.45	-1.0	-0.5	0.52	0.66	0.69
Other Assets	0.84	0.75	0.81	0.36	0.76	0.66	0.46		-0.2	0.38	0.83	0.63	0.52	-0.1	0.48	0.56	0.18	-0.33	-0.33	0.87	0.68	-0.45	-0.73	0.62	0.88	0.84
Short Term Investments	0.12	0.02	-0.34	-0.31	0.09	-0.64	0.09	-0.2		-0.84	-0.03	-0.17	-0.1	0.79	-0.33	-0.7	-0.85	0.08	0.08	0.19	0.15	-0.06	-0.11	-0.07	0.15	0.26
Inventory	0.19	0.34	0.69	0.22	0.2	0.9	0.02	0.38	-0.84		0.29	0.55	0.34	-0.72	0.69	0.92	0.84	-0.4	-0.4	0.02	0.28	-0.03	-0.27	0.33	0.05	0.0
Other Current Assets	0.94	0.97	0.86	0.59	0.93	0.48	0.62	0.83	-0.03	0.29		0.78	0.75	0.29	0.73	0.33	-0.15	-0.75	-0.75	0.84	0.9	-0.61	-0.94	0.91	0.91	0.82
Total Liab	0.69	0.85	0.89	0.28	0.76	0.67	0.31	0.63	-0.17	0.55	0.78		0.73	0.01	0.79	0.58	0.15	-0.74	-0.74	0.5	0.85	-0.3	-0.84	0.77	0.64	0.52
Treasury Stock	0.64	0.83	0.73	0.6	0.68	0.34	0.42	0.52	-0.1	0.34	0.75	0.73		0.31	0.59	0.25	-0.15	-0.8	-0.8	0.53	0.82	-0.4	-0.84	0.91	0.61	0.44
Intangible Assets	0.31	0.31	-0.13	0.25	0.34	-0.65	0.31	-0.1	0.79	-0.72	0.29	0.01	0.31		-0.07	-0.76	-0.98	-0.34	-0.34	0.3	0.35	-0.28	-0.36	0.37	0.34	0.3
Common Stock	0.65	0.79	0.87	0.45	0.66	0.68	0.33	0.48	-0.33	0.69	0.73	0.79	0.59	-0.07		0.6	0.25	-0.88	-0.88	0.37	0.76	-0.32	-0.74	0.78	0.43	0.4
Property Plant Equipment	0.28	0.37	0.73	0.0	0.28	0.98	0.0	0.56	-0.7	0.92	0.33	0.58	0.25	-0.76	0.6		0.85	-0.23	-0.23	0.19	0.33	-0.01	-0.32	0.24	0.19	0.19
Long Term Debt	-0.19	-0.14	0.3	-0.13	-0.21	0.76	-0.24	0.18	-0.85	0.84	-0.15	0.15	-0.15	-0.98	0.25	0.85		0.15	0.15	-0.23	-0.2	0.21	0.21	-0.19	-0.25	-0.23
Preferred Stock Total Equity	-0.64	-0.84	-0.74	-0.6	-0.69	-0.34	-0.43	-0.33	0.08	-0.4	-0.75	-0.74	-0.8	-0.34	-0.88	-0.23	0.15		1.0	-0.38	-0.82	0.41	0.81	-0.91	-0.46	-0.37
Good Will	-0.64	-0.84	-0.74	-0.6	-0.69	-0.34	-0.43	-0.33	0.08	-0.4	-0.75	-0.74	-0.8	-0.34	-0.88	-0.23	0.15	1.0		-0.38	-0.82	0.41	0.81	-0.91	-0.46	-0.37
Net Tangible Assets	0.94	0.77	0.64	0.45	0.71	0.32	0.69	0.87	0.19	0.02	0.84	0.5	0.53	0.3	0.37	0.19	-0.23	-0.38	-0.38		0.72	-0.67	-0.76	0.66	0.96	0.98
Property Plant And Equipment Net	0.86	0.98	0.86	0.35	0.9	0.47	0.45	0.68	0.15	0.28	0.9	0.85	0.82	0.35	0.76	0.33	-0.2	-0.82	-0.82	0.72		-0.43	-0.99	0.89	0.78	0.72
Net Debt	-0.68	-0.52	-0.41	-0.63	-0.37	-0.17	-1.0	-0.45	-0.06	-0.03	-0.61	-0.3	-0.4	-0.28	-0.32	-0.01	0.21	0.41	0.41	-0.67	-0.43		0.48	-0.5	-0.64	-0.67
Retained Earnings	-0.89	-0.99	-0.87	-0.43	-0.94	-0.46	-0.5	-0.73	-0.11	-0.27	-0.94	-0.84	-0.84	-0.36	-0.74	-0.32	0.21	0.81	0.81	-0.76	-0.99	0.48		-0.92	-0.83	-0.74
Non Current Assets Total	0.82	0.94	0.82	0.72	0.82	0.37	0.52	0.62	-0.07	0.33	0.91	0.77	0.91	0.37	0.78	0.24	-0.19	-0.91	-0.91	0.66	0.89	-0.5	-0.92		0.74	0.61
Non Currrent Assets Other	0.94	0.84	0.7	0.48	0.82	0.34	0.66	0.88	0.15	0.05	0.91	0.64	0.61	0.34	0.43	0.19	-0.25	-0.46	-0.46	0.96	0.78	-0.64	-0.83	0.74		0.94
Cash And Short Term Investments	0.95	0.76	0.63	0.37	0.71	0.33	0.69	0.84	0.26	0.0	0.82	0.52	0.44	0.3	0.4	0.19	-0.23	-0.37	-0.37	0.98	0.72	-0.67	-0.74	0.61	0.94

Click cells to compare fundamentals

SpringWorks Therapeutics Account Relationship Matchups

SpringWorks Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	334.8M	576.2M	452.5M	630.2M	725.8M	762.1M
Other Current Liab	9.3M	14.9M	25.4M	39.2M	65.6M	68.8M
Total Current Liabilities	12.0M	17.6M	30.0M	51.0M	78.2M	82.1M
Total Stockholder Equity	322.1M	557.1M	422.4M	(569.9M)	626.2M	657.5M
Accounts Payable	2.7M	1.4M	3.4M	8.0M	7.4M	7.8M
Cash	327.7M	147.1M	104.0M	67.5M	176.1M	184.9M
Other Assets	1.7M	2.6M	3.3M	3.2M	3.7M	2.2M
Other Current Assets	3.7M	4.9M	9.4M	7.5M	12.7M	13.3M
Total Liab	12.8M	19.1M	30.1M	72.1M	99.6M	104.5M
Property Plant Equipment	795K	3.0M	4.2M	18.3M	16.4M	14.7M
Net Tangible Assets	322.1M	557.1M	422.4M	558.2M	641.9M	336.2M
Property Plant And Equipment Net	795K	3.0M	4.2M	18.3M	24.1M	25.3M
Net Debt	(327.7M)	(144.4M)	(102.7M)	(62.2M)	(169.0M)	(177.4M)
Retained Earnings	(73.0M)	(118.6M)	(292.5M)	(569.9M)	(895.0M)	(850.3M)
Non Current Assets Total	3.5M	62.8M	69.6M	30.5M	224.9M	236.1M
Non Currrent Assets Other	1.7M	2.6M	3.3M	3.2M	4.2M	2.5M
Cash And Short Term Investments	327.7M	508.5M	373.5M	597.0M	479.2M	368.0M
Common Stock Shares Outstanding	43.0M	43.3M	48.5M	53.3M	63.1M	49.5M
Liabilities And Stockholders Equity	334.8M	576.2M	452.5M	(497.9M)	725.8M	762.1M
Non Current Liabilities Total	789K	1.5M	129K	21.0M	21.4M	13.9M
Other Stockholder Equity	395.1M	675.6M	715.2M	761K	1.5B	1.6B
Net Invested Capital	322.1M	557.1M	422.4M	558.2M	626.2M	386.6M
Long Term Investments	976K	57.2M	62.1M	9.0M	185.3M	194.6M
Property Plant And Equipment Gross	795K	1.1M	5.2M	19.5M	26.7M	28.1M
Total Current Assets	331.4M	513.4M	382.9M	599.8M	500.9M	374.9M
Accumulated Other Comprehensive Income	(334.8M)	41K	(312K)	(767K)	1.2M	1.3M
Net Working Capital	319.4M	495.8M	352.9M	548.7M	422.7M	344.6M

SpringWorks Therapeutics Investors Sentiment

The influence of SpringWorks Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in SpringWorks. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to SpringWorks Therapeutics' public news can be used to forecast risks associated with an investment in SpringWorks. The trend in average sentiment can be used to explain how an investor holding SpringWorks can time the market purely based on public headlines and social activities around SpringWorks Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

SpringWorks Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for SpringWorks Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average SpringWorks Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on SpringWorks Therapeutics.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards SpringWorks Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, SpringWorks Therapeutics' short interest history, or implied volatility extrapolated from SpringWorks Therapeutics options trading.

Currently Active Assets on Macroaxis

LAAC	Lithium Americas Corp
F	Ford Motor
CHPT	ChargePoint Holdings
AXL	American Axle Manufacturing
ICLN	iShares Global Clean

When determining whether SpringWorks Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of SpringWorks Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Springworks Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Springworks Therapeutics Stock:

How To Invest In SpringWorks

Details

Is SpringWorks Stock a good investment?

Details

What is SpringWorks Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in SpringWorks Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy SpringWorks Stock please use our How to Invest in SpringWorks Therapeutics guide.

You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..

Complementary Tools for SpringWorks Stock analysis

When running SpringWorks Therapeutics' price analysis, check to measure SpringWorks Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpringWorks Therapeutics is operating at the current time. Most of SpringWorks Therapeutics' value examination focuses on studying past and present price action to predict the probability of SpringWorks Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpringWorks Therapeutics' price. Additionally, you may evaluate how the addition of SpringWorks Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	FinTech Suite Use AI to screen and filter profitable investment opportunities
	Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Global Correlations Find global opportunities by holding instruments from different markets
	CEOs Directory Screen CEOs from public companies around the world
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA

Is SpringWorks Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of SpringWorks Therapeutics. If investors know SpringWorks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about SpringWorks Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.15)

Revenue Per Share

0.086

Return On Assets

(0.32)

Return On Equity

(0.55)

The market value of SpringWorks Therapeutics is measured differently than its book value, which is the value of SpringWorks that is recorded on the company's balance sheet. Investors also form their own opinion of SpringWorks Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is SpringWorks Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because SpringWorks Therapeutics' market value can be influenced by many factors that don't directly affect SpringWorks Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between SpringWorks Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if SpringWorks Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, SpringWorks Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

SpringWorks Deferred Long Term Liab vs Current Deferred Revenue Analysis

Deferred Long Term Liab vs Current Deferred Revenue

Deferred Long Term Liab vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Deferred Long Term Liab

Current Deferred Revenue

SpringWorks Therapeutics fundamental ratios Correlations

SpringWorks Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

SpringWorks Therapeutics fundamental ratios Accounts

SpringWorks Therapeutics Investors Sentiment

Currently Active Assets on Macroaxis

Complementary Tools for SpringWorks Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Good Will	+ 1.0	Preferred Stock Total Equity
Property Plant And Equipment Net	+ 0.98	Other Current Liab
Property Plant Equipment	+ 0.98	Accounts Payable
Cash And Short Term Investments	+ 0.98	Net Tangible Assets
Other Current Assets	+ 0.97	Other Current Liab
Non Currrent Assets Other	+ 0.96	Net Tangible Assets

Net Debt	- 1.0	Cash
Retained Earnings	- 0.99	Property Plant And Equipment Net
Retained Earnings	- 0.99	Other Current Liab
Long Term Debt	- 0.98	Intangible Assets
Retained Earnings	- 0.94	Other Current Assets
Retained Earnings	- 0.94	Other Liab